Busetto concludes: "In this analysis of individuals with obesity aged 65 years and older, semaglutide reduced body weight and improved cardiometabolic risk factors compared with placebo, and the safety and efficacy profile of semaglutide was consistent with that reported in the STEP program." He adds: "In many countries, including many high-income countries, the majority of the cases of excess weight actually occur in adults aged 65 years and over, representing a major driver for obesity-related complications and an important cause of reduced quality of life and disability
The MRI-PDFF (31.2% vs.8.3%), ALT (34.6% vs
Human umbilical cord mesenchymal stem cells derived exosome shuttling mir-129-5p attenuates inflammatory bowel disease by inhibiting ferroptosis
not FDA-approved as a standalone drug Key exercise consideration / Avoid training the injured site to failure during the first 2 to 4 weeks of use Safety signal / No serious adverse events reported in available human case series
Advances and challenges of liposome assisted drug delivery
Quick Answer: Yes, most patients experience weight loss plateaus on tirzepatide, typically after the first several months of treatment, though the medication continues to provide metabolic benefits throughout extended therapy